News & Updates

Thirty-day readmissions are similar between patients who had at least one psychotropic medication upon discharge and those who had none, reports a study. However, the former has a higher number of discrepancies that require significantly more discharge interventions during a pharmacist-driven discharge medication reconciliation (DMR).

A test-negative, case-control study demonstrated the real-world effectiveness of the BNT162b2 vaccine (Pfizer–BioNTech) and mRNA-1273 vaccine (Moderna) among healthcare personnel in the US.

People who had an allergic response to the first dose of COVID-19 vaccination or who believe they will have an allergy to vaccination should not let their worries delay getting vaccinated — as most of them can still be fully vaccinated safely, suggest studies presented at ACAAI 2021.

Comedication with the analgesic dipyrone appears to contribute to excess mortality among patients receiving aspirin for secondary cardiovascular disease (CVD) prevention, partly driven by an increase in ischaemic events, a study from Germany has found.

Use of a 4-factor prothrombin complex concentrate (4F-PCC) for oral factor Xa (FXa) inhibitor-related acute major bleeding appears to work for most patients, results of a recent study have shown.

Concomitant administration of the human epidermal growth factor receptor 2 (HER2)–targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) with the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole appears to be safe and does not produce a clinically meaningful change in the pharmacokinetics of T-DXd or DXd, according to a phase I study.

The application of ruxolitinib cream led to significant improvements in facial and total body repigmentation among adolescents and adults with vitiligo, according to two phase III studies presented at EADV 2021.